Drug recall · May 28, 2014
BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets recall
Why: Failed Impurities/Degradation Specifications: High out of specification impurity test results were obtained during stability testing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
BUPRENORPHINE HYDROCHLORIDE Sublingual Tablets, 8 mg, 30-count bottles, Rx only, Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-5379-56, UPC 3 0093-5379-56 2.
- Lots / codes
34009367B, 34009368B, 34009369A, 34009370B, Exp 04/14; 34013141A, 34013142A, Exp 11/14; 34016682A, 34016683A, 34016684A, 34017000A, 34017001A, Exp 08/15
- Quantity
- 53,452 bottles
- Company
- Teva Pharmaceuticals USA, North Wales, PA
- Distribution
- Nationwide and Puerto Rico
- Initiated
- April 7, 2014 · Voluntary: Firm initiated
- Classified
- May 16, 2014
- Reported
- May 28, 2014
- Ended
- November 20, 2014
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Buprenorphine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.